Abraxane Inventor Puts Money to Work in Sorrento
Research - On Monday, Sorrento announced that Dr. Patrick Soon-Shiong made a $41 million investment in the company and now owns 19.9% of Sorrento.
Premium: Read NowzPremium
Double Whammy for Oncothyreon Works Well for Our Trade
Research - With data for ONT-380 to be presented at SABCS, Oncothyreon (ONTY) announced it has licensed ONT-380 from partner Array Biopharma (ARRY) for $20 million.
Premium: Read Now
Bluebird Exceeds Expectations at ASH
Research - Bluebird Bio (BLUE) surprised everyone on Monday evening, exceeding expectations for early data from the LentiGlobin drug candidate.
Read Now
High Fives All Around as Merck Takes Down Cubist
Research - Merck is buying Cubist for $102/share, valuing the antibiotics company at $9.5B including its cash. After the close on Monday, the U.S. District Court in Delaware … Continue Reading
Premium: Read Now
A Short-term Chart Trade and Options Idea for this Upcoming Data Release
Research - This company has a data release coming imminently. We've outlined one equity, and one options strategy for the event.
Premium: Read Now
Trim this Position for an 18% Gain
Research - This thesis played out beautifully, and it's time to take some profit - 18% in just two weeks.
Premium: Read NowTake Advantage of this Trading Channel Before Year-End
Research - In the relative near-term, XOMA Corporation (XOMA) is guiding to complete and release results from EYEGUARD-B, a phase III study of the company’s lead drug candidate gevokizumab … Continue Reading
Premium: Read Now